What is Gujarat Kidney and Super Speciality IPO GMP Today?
The Latest GMP of Gujarat Kidney and Super Speciality IPO GMP is ₹11.
Gujarat Kidney and Super Speciality IPO GMP
| DATE | GMP (GREY MARKET PREMIUM) | EXPECTED LISTING GAINS |
|---|---|---|
| 24-Dec-2025 | 0 | 0 |
| 23-Dec-2025 | 0 | 0 |
| 22-Dec-2025 | 0 | 0 |
| 21-Dec-2025 | 0 | 0 |
| 20-Dec-2025 | 7 | 896 |
| 19-Dec-2025 | 11 | 1,408 |
| 18-Dec-2025 | 11 | 1,408 |
IPO Grey Market Premium (GMP) – Gujarat Kidney and Super Speciality IPO GMP
The grey market premium (GMP) represents the informal trading price in grey market of an IPO before it officially lists on the stock exchange. The GMP can provide an early snapshot of investor sentiment and the expected demand for shares once they are listed. A higher GMP generally suggests positive market expectations, while a lower or negative GMP may indicate cautious sentiment.
It is important to remember that GMP values are purely indicative and can change rapidly due to short-term market factors, speculative trading, or investor perception. They do not guarantee how the IPO will perform on the listing day.
Investors should not base their investment decision solely on GMP. Instead, a careful analysis of the company’s business model, financial health, industry position, and growth potential should guide the decision to participate in the IPO. Using GMP as one of many reference points can help, but relying on it alone carries significant risk.
Company Brief – Gujarat Kidney and Super Speciality Limited – Gujarat Kidney and Super Speciality IPO GMP
Gujarat Kidney and Super Speciality Limited is a regional healthcare company operating a chain of multi-speciality hospitals and related healthcare services in the state of Gujarat. The company focuses on secondary and tertiary care, offering comprehensive medical services including nephrology, urology, general surgery, diagnostics, pharmacy services, and specialized treatment procedures.
On a consolidated basis, the company operates seven multi-speciality hospitals and four pharmacies across key cities including Vadodara, Godhra, Bharuch, Borsad, and Anand. Its healthcare infrastructure includes a total bed capacity of 490 beds, with an approved capacity of 445 beds and operational capacity of 340 beds.
Financially, in the year ended 31 March 2025, Gujarat Kidney and Super Speciality reported total revenue of about ₹40.24 crore and a net profit of approximately ₹9.49 crore, reflecting significant growth in operations and profitability. For the period ended 30 June 2025, the company posted revenue of around ₹15.26 crore and net profit of ₹5.40 crore.
The company’s management and growth strategy is oriented toward expanding healthcare access in under-penetrated regions, enhancing medical infrastructure, and increasing service capabilities through acquisitions and new facility development.
IPO Dates
| Event | Date |
| Issue Opening Date | 22 December 2025 |
| Issue Closing Date | 24 December 2025 |
| Allotment Finalization | 26 December 2025 |
| Refunds Initiated | 29 December 2025 |
| Shares Credited to Demat | 30 December 2025 |
| IPO Listing Date | 30 December 2025 (Tentative) |
IPO Details
| Particulars | Details |
| Price Band | ₹108 – ₹114 per share |
| Face Value | ₹2 per share |
| Market Lot | 128 shares |
| Minimum Retail Investment | ₹13,824 at ₹108 |
| Maximum Retail Investment | Approx ₹1,89,696 (13 lots at ₹114) |
| Issue Size | Approx ₹250.80 crore (2,20,00,000 shares) |
| Issue Type | Book Built Fresh Issue |
| Offer For Sale | None – 100% Fresh Issue |
| Listing Platform | BSE & NSE Mainboards |
| Retail Allocation | 10% |
| NII Allocation | 15% |
| QIB Allocation | 75% |
IPO Reservation Structure
| Investor Category | Allocation |
| Qualified Institutional Buyers (QIBs) | 75% |
| Non-Institutional Investors (NIIs) | 15% |
| Retail Individual Investors | 10% |
Gujarat Kidney and Super Speciality IPO GMP
The Gujarat Kidney and Super Speciality IPO is a fresh issue of approx ₹250.80 crore, priced at ₹108–₹114 per share, and is open for subscription from 22 December 2025 to 24 December 2025. With a lot size of 128 shares and a tentative listing date of 30 December 2025 on both BSE and NSE, this IPO offers an investment opportunity in an expanding regional healthcare provider with increasing revenue and profitability trends. While current GMP sentiment remains neutral, investors should consider the company’s growth strategy, financial performance, and long-term potential before subscribing.